IL‐33 plays a central role in the generation of both these cell types, indicating that biologics targeted at this alarmin [315] may be particularly useful in uncontrolled asthma patients with profound Tc2 cell and/or CD45RO+ ILC2 activity. This evidence concerns the gene IL33 and asthma.